BIOMAT Database Logo BIOMAT Database Logo

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. 1996

U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Ezrath Nashim-Herzog Memorial Hospital, Hadassah Medical School-Hebrew University, Jerusalem, Israel.

BACKGROUND It has been proposed that schizophrenia is associated with underactivity of brain glutamatergic neurotransmission, especially at the level of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Glycine potentiates NMDA receptor-mediated neurotransmission, indicating that it may serve as an effective therapeutic agent in the treatment of schizophrenia. METHODS Eleven treatment-resistant patients with chronic schizophrenia completed a double-blind, placebo-controlled, six-week, randomly assigned, crossover treatment trial of 0.8 g/kg body weight/day of glycine, added to their prior antipsychotic treatment. RESULTS Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0.0001). Significant improvements were also induced in depressive and cognitive symptoms. The greatest reduction in negative symptoms was registered in the patients who had the lowest baseline serum glycine levels. CONCLUSIONS These results extend previous findings and suggest an additional approach to the pharmacotherapy of negative symptoms and cognitive deficits in schizophrenia.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
August 2005, The Journal of clinical psychiatry,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results.
June 2005, Journal of clinical psychopharmacology,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial.
July 2010, Schizophrenia bulletin,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.
July 1995, The American journal of psychiatry,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial.
November 2006, The British journal of psychiatry : the journal of mental science,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.
November 2013, Trials,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial.
February 2012, Journal of clinical psychopharmacology,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial.
January 1997, The American journal of medicine,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial.
December 2003, Biological psychiatry,
U Heresco-Levy, and D C Javitt, and M Ermilov, and C Mordel, and A Horowitz, and D Kelly
Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy.
December 1998, Epilepsia,
Copied contents to your clipboard!